ASCO Daily News: GALAXY – ctDNA Negativity Linked to Improved DFS in Resectable Colorectal Cancer

In an article, Dr. Hiroki Yukami discusses findings from the GALAXY trial presented during the 2024 ASCO Gastrointestinal Cancers Symposium.

!

“These results show that ctDNA is a promising prognostic and predictive marker for recurrence.”—Dr. Hiroki Yukami